Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

Psy­che­delics have made a come­back for men­tal health re­search, with com­pa­nies like start­up biotech ATAI Life Sci­ences rais­ing mil­lions and earn­ing the back­ing of promi­nent in­vestors like Pe­ter Thiel, but there’s a hole at the heart of the resur­gence: Re­searchers still don’t ful­ly un­der­stand how they work.

A new part­ner­ship be­tween ATAI and world-renowned Mass Gen­er­al Hos­pi­tal hopes to change that.

ATAI is the first part­ner in Mass Gen­er­al’s new Cen­ter for Neu­ro­science of Psy­che­delics, which seeks to ad­vance nov­el men­tal health treat­ments through study­ing the mech­a­nisms that un­der­lie the ther­a­peu­tic ef­fects of psy­che­del­ic agents. The Berlin-based com­pa­ny, found­ed in 2018, fo­cus­es on de­vel­op­ing psy­che­del­ic and non-psy­che­del­ic com­pounds for a va­ri­ety of men­tal health needs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER